In the last decade, cancer therapies have increasingly taken the form of combination treatments in which biologic agents play a crucial role. In breast cancer, the treatment strategy is adjusted to intrinsic subtypes such as human epidermal growth factor receptor-2(HER2)-positive. With the introduction of trastuzumab, a monoclonal antibody against HER2, survival has significantly improved in early and metastatic breast cancer. Trastuzumab's patent has now expired and biosimilars are moving into the market. Several clinical trials have led to the approval of 5 different biosimilar trastuzumabs. Results proved similarity between the proposed biosimilar and the reference product without significant differences in efficacy and safety, although follow-up has been short. However, the shorter drug development process with its goal of showing similarity rather than patient benefit uses surrogate endpoints such as pathologic complete response and overall response rate, not survival endpoints in terms of the ‘gold standard' in evaluating cancer therapies. The aim of this article is to give insight into how to plan and perform a clinical trial to prove equivalence between a biosimilar trastuzumab and its reference product and to elucidate the setup and outcome of published clinical trials.

Keywords:
Biosimilars, Trastuzumab, Herceptin, HER2-directed treatment
1.
European Medicines Agency: Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues (EMA/CHMP/BMWP/ 403543/2010; adoption by CHMP 30 May 2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf.
2.
European Medicines Agency: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005). Effective date 1 June 2006 (revised 3 June 2013). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.
3.
Food and Drug Administration: Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for industry. FDA, 2016. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf; accessed December 2018.
4.
Food and Drug Administration: Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. FDA, 2015. www.fda.gov/downloads/drugs/guidances/ucm291128.pdf; accessed December 2018.
5.
European Medicines Agency: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev 1), 18 December 2014. www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf; accessed December 2018.
6.
Jacobs I, Ewesuedo R, Lula S, Zacharchuk C: Biosimilars for the treatment of cancer: a systematic review of published evidence. BioDrugs 2017;31:1-36.
7.
ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials E9. 5 February 1997. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf; accessed December 2018.
8.
ICH Harmonised Tripartite Guideline: Choice of control group and related issues in clinical trials E10. 20 July 2000. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf; accessed December 2018.
9.
Nixon NA, Hannouf MB, Verma S: The evolution of biosimilars in oncology, with a focus on trastuzumab. Curr Oncol 2018;25(suppl 1):S171-S179.
10.
Thill M: New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Rev Anticancer Ther 2015;15:331-338.
11.
Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-172.
12.
Spring LM, Fell G, Arfe A, et al: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: individual patient-level meta-analyses of over 27,000 patients. SABCS 2018;GS2-G03.
13.
Jackisch C, Scappaticci FA, Heinzmann D, et al: Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Future Oncol 2015;11:61-71.
14.
Im YH, Odarchenko P, Grecea D, et al: Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (mBC) as first-line treatment. J Clin Oncol 2013;31:629.
15.
Stebbing J, Baranau Y, Baryash V, et al: CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017;18:917-928.
16.
Pegram MD, Bondarenko I, Zorzetto MMC, et al: PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer 2018;DOI: 10.1038/s41416-018-0340-2.
17.
Lammers PE, Dank M, Masetti R, et al: Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer 2018;119:266-273.
18.
Von Minckwitz G, Colleoni M, Kolberg HC, et al: Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 2018;19:987-998.
19.
Pivot X, Bondarenko I, Nowecki Z, et al: Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol 2018;36:968-974.
20.
Pivot X, Bondarenko I, Nowecki Z, et al: A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results. Eur J Cancer 2018;93:19-27.
21.
Rugo HS, Barve A, Waller CF, et al.; Heritage Study Investigators: Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 2017;317:37-47.
22.
Kummel S, Wimberger P, von Minckwitz G, Nekljudova V, Denkert C, Just M: Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2 × 2 factorial design (GeparX) - an interim safety analysis. J Clin Oncol 2018;36:abstr 569.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.